PHARMACOKINETICS OF REBOXETINE IN HEALTHY VOLUNTEERS W/ DIFFERENT ETH

瑞波西汀在健康志愿者体内的药代动力学

• 批准号: 6306598
• 负责人: RUSSELL Elliott POLAND
• 金额: $ 0.1万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6306598
• 关键词: African American; Asian Americans; antidepressants; caucasian American; clinical research; clinical trial phase I; cytochrome P450; drug metabolism; human subject; pharmacokinetics; racial /ethnic difference

Numerous studies indicate that ethnicity can influence the pharmacokinetics of a variety of pharmacologic agents. In part, this is due to differences in the act- ivity of P450 enzymes (mostly) in the liver which are involved in drug metabol- ism. In order to understand this issue further, evaluation of the pharmacokinet- ics of a new antidepressant, Reboxetine, in African-American, Asian (Chinese) and Caucasian normal volunteers will be done. Reboxetine is currently approved in Europe for the treatment of depression and currently Phase III studies are being performed with the compound."

大量研究表明，种族可以影响多种药物的药代动力学。在某种程度上，这是由于肝脏中参与药物代谢的P450酶（大部分）的活性不同。为了进一步了解这一问题，我们将对一种新的抗抑郁药瑞波西汀在非裔美国人、亚洲人（中国人）和白种人正常志愿者中的药代动力学进行评估。瑞波西汀目前在欧洲被批准用于治疗抑郁症，目前正在进行该化合物的III期研究。”